Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph not_applicable

33%

Ph phase_2

33%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

1(33.3%)

Phase 3Large-scale testing

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 21 (33.3%)

Phase 31 (33.3%)

N/A1 (33.3%)

Trials by Status

completed3100%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_2

Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients

NCT04049851

completednot_applicable

Ocular Changes After Ivermectin - (DOLF IVM/Oncho)

NCT03517462

completedphase_3

A Preventive Treatment for Migrant Workers at High-risk of COVID-19

NCT04446104

Clinical Trials (3)

Showing 3 of 3 trials

NCT04049851Phase 2

Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients

Completed

NCT03517462Not Applicable

Ocular Changes After Ivermectin - (DOLF IVM/Oncho)

Completed

NCT04446104Phase 3

A Preventive Treatment for Migrant Workers at High-risk of COVID-19

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3